[On the development of an oral preparation of meproscillarin (author's transl)].

Analytical methods of determination, investigations of stability and the behaviour of the substance in artificial gastric and intestinal fluids are the bases for the formulation of an oral preparation of 14-hydroxy-3beta-[4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (meproscillarin, Clift). The problems of developing a stable form, the maintenance of uniform content and the bioavailability are discussed.